

Allenic Suicide Substrates. New Inhibitors of Vitamin B₆ Linked Decarboxylases[†]

A. L. Castelhana, D. H. Pliura, G. J. Taylor, K. C. Hsieh, and A. Krantz*

Syntex Inc., Mississauga, Ontario, Canada L5M 2B3

Received December 19, 1983

α -Amino acids that are fully functionalized at the α -carbon often possess useful biological activity.¹ In a number of instances unsaturation in the form of an α -vinyl or an α -ethynyl substituent radically alters the properties of the parent amino acids, converting them from substrates to potent inactivators of their target enzymes.² Many of these compounds are of recent vintage and have been conceived as suicide inhibitors on the grounds that a highly reactive Michael acceptor capable of trapping an active site nucleophile, will be unmasked during the course of enzyme catalysis.³⁻⁸


α -Allenic α -amino acids are attractive candidates for the specific inhibition of vitamin B₆ linked decarboxylases. Besides possessing the latent reactivity of β,γ -unsaturated α -amino acids, the chirality bestowed by an asymmetric allenic element can be exploited as a further refinement in the design of inhibitors of narrow specificity.

Despite their potential as "mechanism-based" inhibitors, not a single example of α -allenic α -amino acids has been reported. In principle, the Claisen rearrangement is an elegant way of translocating a three-carbon unit with concomitant interconversion of propargylic and allenic moieties.⁹ A recent article by Bartlett¹⁰ has discussed the limitations of effecting the ester-enolate Claisen rearrangement en route to β,γ -unsaturated α -amino acids. An alternative approach mediated by oxazolones leads to *N*-benzoyl- α -amino acids that carry an unsaturated side chain but suffers from the difficulty of hydrolyzing the resulting benzamide without affecting the side chain.^{10,11}

We have now established the generality of the conversion of α -benzamido propargylic esters **2**, to 4-allenic oxazolones **3**, and defined the hydrolytic conditions that must be met in order to salvage α -allenic α -amino acids. The general route to α -allenic α -amino acids is outlined in Scheme I.

Treatment of the appropriate α -amino acid with benzoyl chloride under Schotten-Baumann conditions¹² followed by es-

Scheme I^a



^a (i) PhCOCl, OH⁻; (ii) HOCH₂C≡CR₂, DCC, DMAP; (iii) Ph₃P, CCl₄, NEt₃, CH₃CN; (iv) MeOH, NEt₃; (v) Et₃O⁺BF₄⁻, CH₂Cl₂; (vi) 10% HOAc; (vii) 1.0 N NaOH/MeOH. The *N*-benzoylated **3a**, R₁ = (*N*-benzoylimidazolyl)methyl, is hydrolyzed first to the acid corresponding to **4a** and then treated with 20% HCl at 80 °C for 2 days. En route to allenic ornithine, the δ -lactam, rather than the amino ester **5a**, is isolated prior to acid hydrolysis.

terification with propargylic alcohols¹³ gives the corresponding amido propargylic esters **2** in good yield.¹⁴ 4-Allenic oxazolones **3** are formed by treating amido propargylic esters with triphenylphosphine, triethylamine, and carbon tetrachloride in acetonitrile^{11a} at room temperature to generate putative oxazolones which spontaneously rearrange. Methanolysis of the oxazolones **3** gives benzamido esters. With the exception of the histidine analogue, isolated yields for the conversion of **3** to **4** are 50–100%. Although the hydrolysis of the benzamido group in *N*-benzoyl α -allenic histidine takes place in 20% HCl at 80 °C within 2 days, a ketone side product (2-amino-2-(4-imidazolylmethyl)-4-oxopentanoic acid (**7**)) is also formed in about 30% yield. Acid hydrolysis of the other amido esters requires more stringent conditions and generally results in hydration of the allenic moiety. Deprotection of most of the α -allenic α -benzamido esters that we have investigated is accomplished in yields of 50–80% by treating the precursor benzamido esters with freshly prepared Meerwein's reagent,¹⁵ evaporating CH₂Cl₂, and hydrolyzing the residual imidate with 10% aqueous acetic acid.¹⁶ Saponification (1.0 N NaOH in MeOH) of the amino ester **5** gives, in excellent yield, after ion-exchange chromatography (Bio-Rad Ag 50W-X8 column eluting with 20% aqueous pyridine), the α -allenic α -amino acids **6**.¹⁷

(12) Greenstein, J. P.; Winitz, M. "Chemistry of the Amino Acids"; Wiley: New York, 1961; Vol. 2.

(13) Hassner, A.; Alexanian, V. *Tetrahedron Lett.* **1978**, 46, 4475.

(14) *N*-Benzoylhistidine propargyl ester was prepared according to: Beyerman, H. C.; Maat, L.; Van Zon, A. *Recl. Trav. Chim. Pays-Bas* **1972**, 91, 246. Those amino acids carrying secondary functionality required further derivatization. Thus hydroxyl or amino moieties were benzoylated, carboxy groups were esterified, and imidazoles were tosylated or benzoylated to provide protection.

(15) Chern, F. M. F.; Benoiton, N. L. *Can. J. Chem.* **1977**, 55, 1433.

(16) Muxfeldt, H.; Rogalski, W. *J. Am. Chem. Soc.* **1965**, 87, 933.

[†] Contribution no. 187 from the Institute of Bio-Organic Chemistry, Syntex Research.

(1) (a) Sourkes, T. L. *Arch. Biochem. Biophys.* **1954**, 51, 444. (b) Metcalf, B. W. *Ann. Rep. Med. Chem.* **1981**, 16, 289. (c) Maycock, A. L.; Aster, S. D.; Patchett, A. A. In "Drug Action and Design: Mechanism-Based Enzyme Inhibitors"; Kalman, T. I., Ed.; Elsevier N. Holland: New York, 1979; p 115.

(2) Ribereau-Gayon, G.; Danzin, C.; Palfreyman, M. G.; Aubry, M.; Wagner, J.; Metcalf, B. W.; Jung, M. J. *Biochem. Pharmacol.* **1979**, 28, 1331.

(3) Rando, R. R. *Science (Washington, D.C.)* **1974**, 185, 320; *Acc. Chem. Res.* **1975**, 8, 281.

(4) Walsh, C. *Tetrahedron* **1982**, 38, 871; *Trends Pharmacol. Sci.* **1983**, 5, 254.

(5) Kalman, T. I. *Drug Dev. Res.* **1981**, 1, 311.

(6) Alston, T. A. *Pharmacol. Ther.* **1981**, 12, 1.

(7) (a) Abeles, R. H. *Chem. Eng. News* **1983**, 61, 56. (b) Abeles, R. H.; Maycock, A. L. *Acc. Chem. Res.* **1976**, 9, 313.

(8) Jung, M. J.; Koch-Weser, J. In "Molecular Basis of Drug Action"; Singer, T. P.; Ondarza, R. N., Eds.; Elsevier N. Holland: New York, 1981; p 135. (b) For a serious alternative mechanistic viewpoint, see: Likos, J. J.; Ueno, H.; Fieldhaus, R. W.; Metzler, D. E. *Biochemistry* **1982**, 21, 4377.

(9) Bennett, G. B. *Synthesis* **1977**, 589.

(10) Bartlett, P. A.; Barstow, J. F. *J. Org. Chem.* **1982**, 47, 3933.

(11) (a) Kubel, B.; Hofle, G.; Steglich, W. *Angew. Chem., Int. Ed. Engl.* **1975**, 14, 58. (b) Engel, N.; Kubel, B.; Steglich, W. *ibid.* **1977**, 16, 394. (c) Kubel, B.; Gruber, P.; Hurnaus, R.; Steglich, W. *Chem. Ber.* **1979**, 112, 128.

Our preliminary results indicate that α -allenic α -amino acids can be potent, time-dependent inactivators of vitamin B₆ linked amino acid decarboxylases. For example, α -allenic DOPA (**6a**, R = 3,4-dihydroxybenzyl; R₂ = R₃ = H) rapidly inactivates porcine kidney aromatic amino acid decarboxylase (AADC, EC 4.1.1.26) with t_{50} = 6 min at 100 μ M inhibitor, ([I]/[E] = 64) at 37 °C and pH 6.8. By comparison, α -vinyl- and α -ethynyl-DOPA at 100 μ M are reported to have t_{50} = 20 min under similar conditions. In the presence of the substrate 5-hydroxy-L-tryptophan (500 μ M), inactivation of AADC by α -allenic DOPA is retarded such that t_{50} = 12 min at 100 μ M inhibitor. The protection afforded by natural substrates demonstrates the active-site-directed nature of the inactivation. Biphasic, complete (>90%), and essentially irreversible¹⁸ inactivation is characteristic of the inhibition of mammalian AADC by α -allenic aromatic amino acids. α -Vinyl- and α -ethynyl-DOPA were reported to inactivate by pseudo-first-order kinetics^{1c} but inactivation is incomplete (<70%), and up to 85% of the original activity can be recovered after exhaustive dialysis.^{1c,2}

An important aspect of this work is that the diastereomeric pairs of chiral allenic aromatic amino acids **6b** (R = 3-hydroxybenzyl) differ in their abilities to inactivate mammalian and bacterial AADC.¹⁹ There is little variation (t_{50} = 20, 22, and 35 min at [I] = 2 mM) in the abilities of allenic *m*-tyrosine inhibitors **6a** or the separate diastereomeric pairs of **6b** (isomers I and II,²⁰ respectively) to inactivate bacterial tyrosine decarboxylase (EC 4.1.1.25). However, one diastereomeric pair (isomer I) is at least an order of magnitude more effective than the other (isomer II) against mammalian AADC (t_{50} = 4.5 and 85 min, respectively, at [I] = 100 μ M).²¹

This work demonstrates that the chirality of the allene can have a significant effect on the potency and specificity of the suicide inhibitor. Studies of the differential inactivation of vitamin B₆ linked enzymes by chiral allenic amino acids are continuing.

(17) Compounds **6** (R₂ = R₃ = H), including α -allenic Phe, Tyr, Glu, His, Lys, or DOPA were obtained as racemates and were fully characterized by IR, ¹H and ¹³C NMR, mass spectra, and micro analysis. For example, α -allenic *m*-tyrosine: mp 242–245 °C dec; IR (KBr) ν_{\max} 1960 cm⁻¹ (C=C=C); ¹H NMR δ (D₂O) 3.2 (AB, J_{AB} = 13.29 Hz, 2 H, CH₂Ph), 5.15 (m, 2 H, CH₂=C), 5.17 (m, 1 H, HC=C), 6.8–7.6 (m, 4 H, Ph). Anal. Calcd for C₁₂H₁₃NO₃: C, 65.7; H, 6.00; N, 6.40. Found: C, 64.93; H, 6.22; N, 6.26. α -Allenic histidine·2HCl: mp 205 °C dec; IR (KBr) ν_{\max} 1977 cm⁻¹ (C=C=C); ¹H NMR δ (D₂O) 3.5 (AB, J_{AB} = 14.57 Hz, 2 H, CH₂), 5.25 (m, 2 H, H₂C=C), 5.7 (m, 1 H, HC=C), 7.45 (s, 1 H, Im CH), 8.75 ppm (s, 1 H, ImCH); ¹³C NMR δ (D₂O) 209.0 (C=C=C); MH⁺ 194. α -Allenic histidine·H₂O: anal. Calcd for C₉H₁₃NO₃: C, 51.18; H, 6.20; N, 19.89. Found: C, 51.04; H, 6.37; N, 20.13. α -Allenic ornithine·HCl: mp 210 °C dec; IR (KBr) ν_{\max} 1962 cm⁻¹ (C=C=C); ¹H NMR δ (D₂O) 1.94 (m, 4 H, CH₂), 3.1 (t, 2 H, CH₂N), 5.2 (m, 2 H, H₂C=C), 5.6 (m, 1 H, HC=C); ¹³C NMR δ (D₂O) 208.9 (C=C=C); MH⁺ 171. α -Allenic glutamic acid: mp 171 °C dec; IR (KBr) ν_{\max} 1962 cm⁻¹ (C=C=C); ¹H NMR δ (D₂O) 2.3–2.8 (m, 4 H, CH₂), 5.25 (m, 2 H, H₂C=C), 5.6 (m, 1 H, HC=C); ¹³C NMR δ (D₂O) 209.1 (C=C=C); MH⁺ 186. α -Allenic DOPA: mp 230–240 °C dec; IR (KBr) ν_{\max} 1955 cm⁻¹ (C=C=C); ¹H NMR δ (D₂O) 3.15 (AB, 2 H, J = 14.5 Hz, CH₂Ph), 5.15 (app d, 2 H, H₂C=C), 5.65 (app t, 1 H, HC=C), 6.8 (m, 3 H, Ph); M⁺ 235, MH⁺ 236.

(18) No more than 10% of AADC activity was recovered after Sephadex G-25 gel filtration or exhaustive dialysis at pH 7.2 in the presence of exogenous PLP for mammalian AADC inactivated by the α -allenic analogues of DOPA, *m*-tyrosine, or phenylalanine.

(19) DOPA decarboxylase (mammalian AADC) from porcine kidney was purified by minor modification to procedures outlined in: (a) Borri-Voltattorni, C.; Minelli, A.; Vecchini, P.; Fiori, A.; Turano, C. *Eur. J. Biochem.* **1979**, *93*, 181. (b) Rudd, E. A.; Thanassi, J. W. *Biochemistry* **1981**, *20*, 7469. L-Tyrosine decarboxylase *ex Streptococcus faecalis* was purchased from Sigma Chemical Co.

(20) Diastereomeric pairs of chiral allenic *m*-tyrosine analogues **6b** (R = 3-hydroxybenzyl, R₂ = CH₃, R₃ = H) were isolated by semipreparative HPLC-RP-18 eluting with 15% (v/v) CH₃CN in 30 mM ammonium acetate at pH 6.0. Isomer I designates the first diastereomeric pair to elute under these conditions followed by isomer II.

(21) Incubations were carried out with inhibitors at 37 °C and pH 6.8 against mammalian DOPA decarboxylase¹⁹ or at pH 5.5 with bacterial L-tyrosine decarboxylase. Residual activities were determined by HPLC/electrochemical monitoring of dopamine or *p*-tyramine production by mammalian or bacterial enzymes, respectively.

Acknowledgment. We thank Valerie Robinson for her expert NMR assistance, Dr. John Moffatt, Syntex (Palo Alto), for helpful discussion, and Lynn Jacob for her many specialized contributions. We are especially grateful to Doreen Nathaniel for carrying out preliminary experiments with AADC.


Total Synthesis and Stereochemistry of Hybridalactone

E. J. Corey* and Biswanath De

Department of Chemistry, Harvard University
Cambridge, Massachusetts 02138

Received February 7, 1984

Hybridalactone, a macrocyclic lactone from the marine alga *Laurencia hybrida* was recently shown to have the gross structure **1** on the basis of proton magnetic resonance (¹H NMR) and mass



spectral (MS) studies.¹ Although a partial assignment of stereochemistry was also made (Δ^5 - and Δ^8 -double bonds both *Z*, H-10/H-11 trans, H-10/H-14 trans, H-11/H-12 cis, H-16/H-18 cis), neither the absolute configuration nor the relative configurations at carbons 14–16 were ascertained. Because of our interest in novel eicosanoids² and the intriguing question of the biosynthesis

(1) Higgs, M. D.; Mulheirn, L. J. *Tetrahedron* **1981**, *37*, 4259.

(2) See: (a) Corey, E. J. *Experientia* **1982**, *38*, 1259; (b) *Ibid.* **1983**, *39*, 1084. (c) Corey, E. J.; Schmidt, G.; Shimoji, K. *Tetradron Lett.* **1983**, *24*, 3169.